Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 8-23

  Kim, Moon Sun ^a,b   Ong, Madeleine ^a   Qu, Xianqin ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alcohol hepatitis; Alcoholic liver disease; Combination therapy; Conventional medicines; Hepatic inflammation; Hepatic lipid metabolism; Natural medicines

Indexed keywords

ALPHA TOCOPHEROL; BETAINE; CARVEDILOL; COLCHICINE; CORTICOSTEROID; CURCUMIN; EPIGALLOCATECHIN GALLATE; GINSENOSIDE; GLYCYRRHIZIC ACID; LIV 52; METADOXINE; METFORMIN; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; POLYPHENOL; PREDNISONE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; SILYMARIN; BIOLOGICAL PRODUCT; PLANT MEDICINAL PRODUCT;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALTERNATIVE MEDICINE; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; DIET SUPPLEMENTATION; DRUG SAFETY; DRUG TARGETING; FATTY LIVER; FENUGREEK; HERBAL MEDICINE; HUMAN; LIFESTYLE MODIFICATION; LIVER DEVELOPMENT; NONHUMAN; NUTRITION; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEA; TRANSPLANTATION; COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; LIFESTYLE; LIVER DISEASES, ALCOHOLIC;

BIOLOGICAL PRODUCTS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; HUMANS; LIFE STYLE; LIVER DISEASES, ALCOHOLIC; PLANT PREPARATIONS;

EID: 84953403595     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.8     Document Type: Review

References (166)

1. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator-Activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478 [PMID: 10930382]
2. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]
3. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127: S87-S96 [PMID: 15508108]
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101]
5. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013; 59: 160-168 [PMID: 23511777 DOI: 10.1016/j.jhep.2013.03.007]
6. World Health Organization. Global status report on alcohol and health 2011. Available from: URL: http://www.who. int/substance-Abuse/publications/global-Alcohol-report/msbgsruprofiles.pdf
7. Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, Yin H, Choi A, Bennett ES, You M. Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 2013; 304: G38-G47 [PMID: 23139221 DOI: 10.1152/ajpgi.00309.2012]
8. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
9. Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Hepatology 2007; 46: 2032-2039 [PMID: 18046720 DOI: 10.1002/hep.22010]
10. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1-G6 [PMID: 15194557 DOI: 10.1152/ajpgi.00056.2004]
11. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 2: 92-100 [PMID: 16191414]
12. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.00013.2007]
13. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-Alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007; 32: 453-468 [PMID: 18198478]
14. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N, Thurman RG. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000; 15 Suppl: D20-D25 [PMID: 10759216]
15. Veldt BJ, Lainé F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, MoIrand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-98 [PMID: 11804670]
16. Hanje AJ, Fortune B, Song M, Hill D, McClain C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract 2006; 21: 255-272 [PMID: 16772543]
17. Luca A, García-Pagán JC, Bosch J, Feu F, Caballería J, Groszmann RJ, Rodés J. Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 1997; 112: 1284-1289 [PMID: 9098014]
18. Kadden R. Cognitive-behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence. US: Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 1995
19. Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99: 811-828 [PMID: 15200577 DOI: 10.1111/j.1360-0443.2004.00763.x]
20. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005; 72: 1775-1780 [PMID: 16300039]
21. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281: 1318-1325 [PMID: 10208148]
22. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from populationbased surveillance. J Clin Gastroenterol 2010; 44: 301-307 [PMID: 19745759 DOI: 10.1097/MCG.0b013e3181b3f760]
23. Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 1994; 10: 657-664 [PMID: 7672043]
24. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248-1257 [PMID: 1476147]
25. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111 [PMID: 8985274 DOI: 10.1002/hep.510250120]
26. Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis 2012; 16: 805-826 [PMID: 23101983 DOI: 10.1016/j.cld.2012.08.009]
27. McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res 2011; 35: 815-820 [PMID: 21284673 DOI: 10.1111/j.1530-0277.2010.01405.x]
28. Hirsch S, de la Maza MP, Gattás V, Barrera G, Petermann M, Gotteland M, Muñoz C, Lopez M, Bunout D. Nutritional support in alcoholic cirrhotic patients improves host defenses. J Am Coll Nutr 1999; 18: 434-441 [PMID: 10511325]
29. Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011; 4: 63-81 [PMID: 21317995 DOI: 10.1177/1756283X10378925]
30. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005; 26: 391-404 [PMID: 16099027 DOI: 10.1016/j.mam.2005.07.002]
31. Das I, Burch RE, Hahn HK. Effects of zinc deficiency on ethanol metabolism and alcohol and aldehyde dehydrogenase activities. J Lab Clin Med 1984; 104: 610-617 [PMID: 6384394]
32. Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. Am J Pathol 2005; 166: 1681-1690 [PMID: 15920153 DOI: 10.1016/s0002-9440(10)62478-9]
33. Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989; 9: 105-113 [PMID: 2671116]
34. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, Hadengue A. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001; 35: 582-589 [PMID: 11690703 DOI: 10.1016/S0168-8278(01)00190-8]
35. Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, Opolon P, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000; 32: 579-586 [PMID: 10782906 DOI: 10.1016/S0168-8278(00)80219-6]
36. Tome S, Lucey MR. Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 2004; 19: 707-714 [PMID: 15043511 DOI: 10.1111/j.1365-2036.2004.01881.x]
37. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O'Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis-A randomised clinical trial. J Hepatol 2006; 44: 784-790 [PMID: 16469404 DOI: 10.1016/j.jhep.2005.11.039]
38. Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512 [PMID: 1531090 DOI: 10.1056/nejm199202203260802]
39. Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, Valla D, Poupon R, Chaput JC, Naveau S. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-1369 [PMID: 14647046 DOI: 10.1016/j.hep.2003.09.038]
40. Mathurin P, Beuzin F, Louvet A, Carrié-Ganne N, Balian A, Trinchet JC, Dalsoglio D, Prevot S, Naveau S. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther 2007; 25: 1047-1054 [PMID: 17439505 DOI: 10.1111/j.1365-2036.2007.03302.x]
41. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]
42. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 [PMID: 11113085]
43. De B, Mandal S, Sau D, Mani S, Chatterjee S, Mondal S, Bhattacharya K, Sil K, Bhattacharya R. Pentoxifylline Plus Prednisolone versus Pentoxifylline Only for Severe Alcoholic Hepatitis: A Randomized Controlled Clinical Trial. Ann Med Health Sci Res 2014; 4: 810-816 [PMID: 25328799 DOI: 10.4103/2141-92 48.141562]
44. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198 [PMID: 1858029]
45. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854 [PMID: 23489011 DOI: 10.1111/apt.12279]
46. Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009; (4): CD007339 [PMID: 19821406 DOI: 10.1002/14651858.CD007339. pub2]
47. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Am J Gastroenterol 2010; 105: 14-32; quiz 33 [PMID: 19904248 DOI: 10.1038/ajg.2009.593]
48. Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004; 28: 173-181 [PMID: 14745316 DOI: 10.1097/01. alc.0000108654.77178.03]
49. Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 2002; 27: 173-177 [PMID: 12163146]
50. Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-Adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock 2008; 30: 197-205 [PMID: 18180699 DOI: 10.1097/shk.0b013e318160f417]
51. Le MD, Enbom E, Traum PK, Medici V, Halsted CH, French SW. Alcoholic liver disease patients treated with S-Adenosyl-Lmethionine: an in-depth look at liver morphologic data comparing pre and post treatment liver biopsies. Exp Mol Pathol 2013; 95: 187-191 [PMID: 23886644 DOI: 10.1016/j.yexmp.2013.07.003]
52. Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CH. S-Adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res 2011; 35: 1960-1965 [PMID: 22044287 DOI: 10.1111/j.1530-0277.2011.01547.x]
53. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53: 1023-1034 [PMID: 21319202 DOI: 10.1002/hep.24148]
54. Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008; 60: 790-797 [PMID: 18709650 DOI: 10.1002/iub.124]
55. Shen Z, Liang X, Rogers CQ, Rideout D, You M. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2010; 298: G364-G374 [PMID: 20007851 DOI: 10.1152/ajpgi.00456.2009]
56. Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res 2012; 36: 1587-1599 [PMID: 22413959 DOI: 10.1111/j.1530-0277.2012.01773.x]
57. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE. Metformin prevents alcoholinduced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-2112 [PMID: 16762632 DOI: 10.1053/j.gastro.2006.03.020]
58. Zhu Z, Jiang Z, Zhou J, Zhou D, Wang W, Zhao C, Zhen Z, Nanji AA. Involvement of insulin resistance in the protective effect of metformin against alcoholic liver injury. Alcohol Clin Exp Res 2014; 38: 1510-1519 [PMID: 24797033 DOI: 10.1111/acer.12418]
59. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-A review. Alcohol Clin Exp Res 1999; 23: 991-1007 [PMID: 10397283]
60. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 2003; 27: 1765-1772 [PMID: 14634492 DOI: 10.1097/01.alc.0000093743.03049.80]
61. Gebhardt AC, Lucas D, Ménez JF, Seitz HK. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 1997; 26: 957-961 [PMID: 9328319 DOI: 10.1002/hep.510260423]
62. Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Fang C, Ingelman-Sundberg M, Donohue TM, French SW. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med 2000; 224: 302-308 [PMID: 10964266]
63. Kinde H, Bettey RL, Ardans A, Galey FD, Daft BM, Walker RL, Eklund MW, Byrd JW. Clostridium botulinum type-C intoxication associated with consumption of processed alfalfa hay cubes in horses. J Am Vet Med Assoc 1991; 199: 742-746 [PMID: 1955364]
64. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 2009; 58: 704-720 [PMID: 19359436 DOI: 10.1136/gut.2008.156307]
65. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-247 [PMID: 8171045]
66. Singh AK, Pandey SK, Naresh Kumar G. Pyrroloquinoline quinonesecreting probiotic Escherichia coli Nissle 1917 ameliorates ethanolinduced oxidative damage and hyperlipidemia in rats. Alcohol Clin Exp Res 2014; 38: 2127-2137 [PMID: 24930470 DOI: 10.1111/acer.12456]
67. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-455 [PMID: 23216382 DOI: 10.1111/jgh.12070]
68. Clot P, Tabone M, Aricó S, Albano E. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut 1994; 35: 1637-1643 [PMID: 7828989]
69. Gutiérrez-Ruiz MC, Bucio L, Correa A, Souza V, Hernández E, Gómez-Quiroz LE, Kershenobich D. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol Res 2001; 44: 431-436 [PMID: 11712874 DOI: 10.1006/phrs.2001.0883]
70. Muntoni S, Rojkind M, Muntoni S. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. World J Gastroenterol 2010; 16: 2889-2894 [PMID: 20556834 DOI: 10.3748/wjg.v16.i23.2889]
71. Carmichael FJ, Orrego H, Saldivia V, Israel Y. Effect of propylthiouracil on the ethanol-induced increase in liver oxygen consumption in awake rats. Hepatology 1993; 18: 415-421 [PMID: 8340071 DOI: 10.1002/hep.1840180228]
72. Dureja P, Lucey MR. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol 2010; 52: 759-764 [PMID: 20347501 DOI: 10.1016/j.jhep.2009.12.021]
73. Pageaux GP, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, Fabre JM, Navarro F, Blanc P, Domergue J, Eledjam JJ, Larrey D. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003; 38: 629-634 [PMID: 12713874]
74. Tang H, Boulton R, Gunson B, Hubscher S, Neuberger J. Patterns of alcohol consumption after liver transplantation. Gut 1998; 43: 140-145 [PMID: 9771419]
75. Dumortier J, Guillaud O, Adham M, Boucaud C, Delafosse B, Bouffard Y, Paliard P, Scoazec JY, Boillot O. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007; 102: 1032-1041 [PMID: 17313502 DOI: 10.1111/j.1572-0241.2007.01079.x]
76. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138-148 [PMID: 19951276 DOI: 10.1111/j.1600-6143.2009.02869.x]
77. Zanus G, Carraro A, Vitale A, Gringeri E, D'Amico F, Valmasoni M, D'Amico FE, Brolese A, Boccagni P, Neri D, Srsen N, Burra P, Feltracco P, Bonsignore P, Scopelliti M, Cillo U. Alcohol abuse and de novo tumors in liver transplantation. Transplant Proc 2009; 41: 1310-1312 [PMID: 19460548 DOI: 10.1016/j.transproceed.2009.03. 055]
78. Tomé S, Martinez-Rey C, González-Quintela A, Gude F, Brage A, Otero E, Abdulkader I, Forteza J, Bustamante M, Varo E. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol 2002; 36: 793-798 [PMID: 12044530]
79. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628-637 [PMID: 9404965]
80. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47-73 [PMID: 9258630]
81. French SW. The importance of CYP2E1 in the pathogenesis of alcoholic liver disease and drug toxicity and the role of the proteasome. Subcell Biochem 2013; 67: 145-164 [PMID: 23400920 DOI: 10.1007/978-94-007-5881-0-4]
82. Spengler EK, Dunkelberg J, Schey R. Alcoholic hepatitis: current management. Dig Dis Sci 2014; 59: 2357-2366 [PMID: 24798996 DOI: 10.1007/s10620-014-3173-8]
83. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]
84. Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc (2003) 2010; 50: 407-410 [PMID: 20452916 DOI: 10.1331/JAPhA.2010.08090]
85. Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, Santos PM, Alves MM, Moura MC. Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 2002; 14: 377-381 [PMID: 11943949]
86. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34: 595-603 [PMID: 11526548 DOI: 10.1053/jhep.2001.27445]
87. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391-2397 [PMID: 12358262 DOI: 10.1111/j.1572-0241.2002.05993.x]
88. Arteel GE, Uesugi T, Bevan LN, Gäbele E, Wheeler MD, McKim SE, Thurman RG. Green tea extract protects against early alcoholinduced liver injury in rats. Biol Chem 2002; 383: 663-670 [PMID: 12033455 DOI: 10.1515/bc.2002.068]
89. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43: 89-143 [PMID: 12587987 DOI: 10.1080/10408690390826464]
90. Tedeschi E, Suzuki H, Menegazzi M. Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Ann N Y Acad Sci 2002; 973: 435-437 [PMID: 12485906]
91. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr 2003; 133: 3262S-3267S [PMID: 14519824]
92. Kim JJ, Tan Y, Xiao L, Sun YL, Qu X. Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed Res Int 2013; 2013: 920128 [PMID: 24066304 DOI: 10.1155/2013/920128]
93. Kaviarasan S, Sundarapandiyan R, Anuradha CV. Epigallocatechin gallate, a green tea phytochemical, attenuates alcohol-induced hepatic protein and lipid damage. Toxicol Mech Methods 2008; 18: 645-652 [PMID: 20020850 DOI: 10.1080/15376510701884985]
94. Yuan G, Gong Z, Zhou X, Zhangq P, Sun X, Li X. Epigallocatechin-3-Gallate Ameliorates Alcohol-Induced Liver Injury in Rats. Int J Mol Sci 2006; 7: 204 [DOI: 10.3390/i7070204]
95. Yun JW, Kim YK, Lee BS, Kim CW, Hyun JS, Baik JH, Kim JJ, Kim BH. Effect of dietary epigallocatechin-3-gallate on cytochrome P450 2E1-dependent alcoholic liver damage: enhancement of fatty acid oxidation. Biosci Biotechnol Biochem 2007; 71: 2999-3006 [PMID: 18071271 DOI: 10.1271/bbb.70403]
96. Nussler AK, Hao L, Knobeloch D, Yao P, Nussler NC, Wang Z, Liu L, Ehnert S. Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis 2010; 28: 792-798 [PMID: 21525764 DOI: 10.1159/000324287]
97. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-119 [PMID: 17548790 DOI: 10.1177/153 4735407301825]
98. Comoglio A, Tomasi A, Malandrino S, Poli G, Albano E. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol 1995; 50: 1313-1316 [PMID: 7488251]
99. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland GT. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009; 16: 391-400 [PMID: 19303273 DOI: 10.1016/j.phymed.2009.02.002]
100. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37: 336-339 [PMID: 14506392]
101. Zhang W, Hong R, Tian T. Silymarin's Protective Effects and Possible Mechanisms on Alcoholic Fatty Liver for Rats. Biomol Ther (Seoul) 2013; 21: 264-269 [PMID: 24244810 DOI: 10.4062/biomolther.2013.020]
102. IDel Prete A, Scalera A, Iadevaia MD, MIranda A, Zulli C, Gaeta L, Tuccillo C, Federico A, Loguercio C. Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med 2012; 2012: 837939 [PMID: 22991573 DOI: 10.1155/2012/837939]
103. Purohit V, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, Kaplowitz N, Kharbanda KK, Liu QY, Lu SC, McClain CJ, Swanson C, Zakhari S. Role of S-Adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007; 86: 14-24 [PMID: 17616758]
104. Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007; 46: 314-321 [PMID: 17156888 DOI: 10.1016/j.jhep.2006.08.024]
105. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-163 [PMID: 17112692 DOI: 10.1016/j.ijpharm.2006.09.025]
106. Kharbanda KK, Todero SL, King AL, Osna NA, McVicker BL, Tuma DJ, Wisecarver JL, Bailey SM. Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome. Int J Hepatol 2012; 2012: 962183 [PMID: 22187660 DOI: 10.1155/2012/962183]
107. Shi QZ, Wang LW, Zhang W, Gong ZJ. Betaine inhibits toll-like receptor 4 expression in rats with ethanol-induced liver injury. World J Gastroenterol 2010; 16: 897-903 [PMID: 20143470 DOI: 10.3748/wjg.v16.i7.897]
108. Li YJ, Chen J, Li Y, Li Q, Zheng YF, Fu Y, Li P. Screening and characterization of natural antioxidants in four Glycyrrhiza species by liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. J Chromatogr A 2011; 1218: 8181-8191 [PMID: 21968349 DOI: 10.1016/j.chroma.2011.09.030]
109. Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 2012; 18: 679-684 [PMID: 22363140 DOI: 10.3748/wjg.v18.i7.679]
110. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, Bielenberg J. Antiviral effects of Glycyrrhiza species. Phytother Res 2008; 22: 141-148 [PMID: 17886224 DOI: 10.1002/ptr.2295]
111. Wang CY, Kao TC, Lo WH, Yen GC. Glycyrrhizic acid and 18?-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-?B through PI3K p110? and p110? inhibitions. J Agric Food Chem 2011; 59: 7726-7733 [PMID: 21644799 DOI: 10.1021/jf2013265]
112. Thiyagarajan P, Chandrasekaran CV, Deepak HB, Agarwal A. Modulation of lipopolysaccharide-induced pro-inflammatory mediators by an extract of Glycyrrhiza glabra and its phytoconstituents. Inflammopharmacology 2011; 19: 235-241 [PMID: 21328091 DOI: 10.1007/s10787-011-0080-x]
113. Li XL, Zhou AG. Evaluation of the immunity activity of glycyrrhizin in AR mice. Molecules 2012; 17: 716-727 [PMID: 22241467 DOI: 10.3390/molecules17010716]
114. Wang J, Guo J, Liu S. [Inhibitory effect of glycyrrhizin on NFkappa B binding activity in CCl4 plus ethanol induced liver cirrhosis in rats]. Zhonghua Ganzangbing Zazhi 1999; 7: 42-43 [PMID: 10366987]
115. Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl4-plus ethanolinduced liver cirrhosis in rats. Liver 1998; 18: 180-185 [PMID: 9716228]
116. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-1500 [PMID: 9118029]
117. Huu Tung N, Uto T, Morinaga O, Kim YH, Shoyama Y. Pharmacological effects of ginseng on liver functions and diseases: a minireview. Evid Based Complement Alternat Med 2012; 2012: 173297 [PMID: 22997528 DOI: 10.1155/2012/173297]
118. Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur J Pharmacol 2006; 550: 173-179 [PMID: 17027742 DOI: 10.1016/j.ejphar.2006.08.056]
119. Yokozawa T, Kobayashi T, Oura H, Kawashima Y. Hyperlipemiaimproving effects of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem Pharm Bull (Tokyo) 1985; 33: 3893-3898 [PMID: 4092288]
120. Hou YL, Tsai YH, Lin YH, Chao JC. Ginseng extract and ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis in rats. BMC Complement Altern Med 2014; 14: 415 [PMID: 25344394 DOI: 10.1186/1472-6882-14-415]
121. Song SB, Tung NH, Quang TH, Ngan NT, Kim KE, Kim YH. Inhibition of TNF-?-mediated NF-?B Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res 2012; 36: 146-152 [PMID: 23717114 DOI: 10.5142/jgr.2012.36.2.146]
122. Yuan HD, Kim SJ, Quan HY, Kim DY, Kim GW, Chung SH. Ginsenoside Re attenuates alcoholic fatty liver disease via regulation of AMPK and MAPK pathways in alcohol-fed ICR mice. Proceedings of the Proceedings of the Spring International Ginseng Conference. Jeju, Korea: Spring, 2012: 114
123. Han JY, Lee S, Yang JH, Kim S, Sim J, Kim MG, Jeong TC, Ku SK, Cho IJ, Ki SH. Korean Red Ginseng attenuates ethanolinduced steatosis and oxidative stress via AMPK/Sirt1 activation. J Ginseng Res 2015; 39: 105-115 [PMID: 26045683 DOI: 10.1016/j.jgr.2014.09.001]
124. Hong M, Kim SW, Han SH, Kim DJ, Suk KT, Kim YS, Kim MJ, Kim MY, Baik SK, Ham YL. Probiotics (Lactobacillus rhamnosus R0011 and acidophilus R0052) reduce the expression of toll-like receptor 4 in mice with alcoholic liver disease. PLoS One 2015; 10: e0117451 [PMID: 25692549 DOI: 10.1371/journal.pone.0117451]
125. Kim MS, Lee KT, Iseli TJ, Hoy AJ, George J, Grewal T, Roufogalis BD. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver Int 2013; 33: 1583-1593 [PMID: 23998390 DOI: 10.1111/liv.12287]
126. Anuradha CV, Ravikumar P. Restoration on tissue antioxidants by fenugreek seeds (Trigonella Foenum Graecum) in alloxandiabetic rats. Indian J Physiol Pharmacol 2001; 45: 408-420 [PMID: 11883146]
127. Kochhar A, Nagi M. Effect of supplementation of traditional medicinal plants on blood glucose in non-insulin-dependent diabetics: a pilot study. J Med Food 2005; 8: 545-549 [PMID: 16379570 DOI: 10.1089/jmf.2005.8.545]
128. Shang M, Cai S, Han J, Li J, Zhao Y, Zheng J, Namba T, Kadota S, Tezuka Y, Fan W. [Studies on flavonoids from Fenugreek (Trigonella foenumgraecum L.)]. Zhongguo Zhongyao Zazhi 1998; 23: 614-66, 639 [PMID: 11599360]
129. Kaviarasan S, Ramamurty N, Gunasekaran P, Varalakshmi E, Anuradha CV. Fenugreek (Trigonella foenum graecum) seed extract prevents ethanol-induced toxicity and apoptosis in Chang liver cells. Alcohol Alcohol 2006; 41: 267-273 [PMID: 16574673 DOI: 10.1093/alcalc/agl020]
130. Nickel T, Hanssen H, Sisic Z, Pfeiler S, Summo C, Schmauss D, Hoster E, Weis M. Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur J Nutr 2011; 50: 163-172 [PMID: 20652710 DOI: 10.1007/s00394-010-0125-8]
131. Tang Y, Gao C, Xing M, Li Y, Zhu L, Wang D, Yang X, Liu L, Yao P. Quercetin prevents ethanol-induced dyslipidemia and mitochondrial oxidative damage. Food Chem Toxicol 2012; 50: 1194-1200 [PMID: 22365892 DOI: 10.1016/j.fct.2012.02.008]
132. Kaviarasan S, Viswanathan P, Anuradha CV. Fenugreek seed (Trigonella foenum graecum) polyphenols inhibit ethanol-induced collagen and lipid accumulation in rat liver. Cell Biol Toxicol 2007; 23: 373-383 [PMID: 17453353 DOI: 10.1007/s10565-007-9000-7]
133. Bao W, Li K, Rong S, Yao P, Hao L, Ying C, Zhang X, Nussler A, Liu L. Curcumin alleviates ethanol-induced hepatocytes oxidative damage involving heme oxygenase-1 induction. J Ethnopharmacol 2010; 128: 549-553 [PMID: 20080166 DOI: 10.1016/j.jep.2010.01.029]
134. Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Suyasunanont D, Klaikeaw N. Curcumin decreased oxidative stress, inhibited NFkappaB activation, and improved liver pathology in ethanol-induced liver injury in rats. J Biomed Biotechnol 2009; 2009: 981963 [PMID: 19606259 DOI: 10.1155/2009/981963]
135. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 2003; 284: G321-G327 [PMID: 12388178 DOI: 10.1152/ajpgi.00230.2002]
136. Lee HI, McGregor RA, Choi MS, Seo KI, Jung UJ, Yeo J, Kim MJ, Lee MK. Low doses of curcumin protect alcohol-induced liver damage by modulation of the alcohol metabolic pathway, CYP2E1 and AMPK. Life Sci 2013; 93: 693-699 [PMID: 24063989 DOI: 10.1016/j.lfs.2013.09.014]
137. Rong S, Zhao Y, Bao W, Xiao X, Wang D, Nussler AK, Yan H, Yao P, Liu L. Curcumin prevents chronic alcohol-induced liver disease involving decreasing ROS generation and enhancing antioxidative capacity. Phytomedicine 2012; 19: 545-550 [PMID: 22445643 DOI: 10.1016/j.phymed.2011.12.006]
138. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818 [PMID: 17999464 DOI: 10.1021/mp700113r]
139. Wang L, Wang BE, Wang J, Xiao PG, Tan XH. Herbal compound 861 regulates mRNA expression of collagen synthesis-And degradation-related genes in human hepatic stellate cells. World J Gastroenterol 2008; 14: 1790-1794 [PMID: 18350612 DOI: 10.3748/wjg.14.1790]
140. You H, Wang B, Wang T. [Proliferation and apoptosis of hepatic stellate cells and effects of compound 861 on liver fibrosis]. Zhonghua Ganzangbing Zazhi 2000; 8: 78-80 [PMID: 10861108]
141. Yin C, Ma H, Wang A, Ma X, Jia J, Wang B. [Effect of compound 861 on tissue inhibitor of metalloprotenase 1 gene expression of HSC-T6 cells]. Zhonghua Ganzangbing Zazhi 2002; 10: 197-199 [PMID: 12113678]
142. Baoen W, Tailing W, Jidong J, Hong M, Zhongping D, Xinmin L, Jia L, Aimin W, Linxue Q. Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine. CJIM 1999; 5: 6-11 [DOI: 10.1007/BF02934179]
143. Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. [The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial]. Zhonghua Ganzangbing Zazhi 2004; 12: 467-470 [PMID: 15329205]
144. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-160 [PMID: 9862861 DOI: 10.1002/hep.510290108]
145. Cohen MR. Herbal and complementary and alternative medicine therapies for liver disease. A focus on Chinese traditional medicine in hepatitis C virus. Clin Liver Dis 2001; 5: 461-478, vii [PMID: 11385972]
146. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci 2005; 50: 1807-1812 [PMID: 16187178 DOI: 10.1007/s10620-005-2942-9]
147. Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-1104 [PMID: 10498665 DOI: 10.1002/hep.510300437]
148. Mitra SK, Varma SR, Godavarthi A, Nandakumar KS. Liv.52 regulates ethanol induced PPARgamma and TNF alpha expression in HepG2 cells. Mol Cell Biochem 2008; 315: 9-15 [PMID: 18449625 DOI: 10.1007/s11010-008-9782-9]
149. Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine 2005; 12: 619-624 [PMID: 16194047]
150. Mao YM, Zeng MD, Chen Y, Chen CW, Fu QC, Cai X, Wu SM, Chen YG, Sun Y, Li J, Sui YH, Zhao W, Lu LG, Cao AP, Chen HZ. [Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study]. Zhonghua Ganzangbing Zazhi 2009; 17: 847-851 [PMID: 19958646]
151. Xiao ZW, Zhang W, Ma L, Qiu ZW. Therapeutic effect of magnesium isoglycyrrhizinate in rats on lung injury induced by paraquat poisoning. Eur Rev Med Pharmacol Sci 2014; 18: 311-320 [PMID: 24563429]
152. Zhao J, Wan XY, Luo M, Chen TS, He P. Antifibrotic effects of glycyrrhizin and matrine in vitro and in vivo. Biomedicine Preventive Nutrition 2012; 2: 132-137 [DOI: 10.1016/j.bionut.2011.12.006]
153. Testino G, Leone S, Ansaldi F, Borro P. Silymarin and S-Adenosyl-L-methionine (SAMe): two promising pharmacological agents in case of chronic alcoholic hepathopathy. A review and a point of view. Minerva Gastroenterol Dietol 2013; 59: 341-356 [PMID: 24212353]
154. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005; 43: 901-910 [PMID: 16171893 DOI: 10.1016/j.jhep.2005.08.002]
155. Nakagawa A, Yamaguchi T, Takao T, Amano H. [Five cases of drug-induced pneumonitis due to Sho-saiko-to or interferon-Alpha or both]. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 1361-1366 [PMID: 8821988]
156. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23: 866-870 [PMID: 12885100]
157. Singal AK, Anand BS. Recent trends in the epidemiology of alcoholic liver disease. Clinical Liver Disease 2013; 2: 53-56 [DOI: 10.1002/cld.168]
158. Moghe A, Joshi-Barve S, Ghare S, Gobejishvili L, Kirpich I, McClain CJ, Barve S. Histone modifications and alcohol-induced liver disease: are altered nutrients the missing link? World J Gastroenterol 2011; 17: 2465-2472 [PMID: 21633651 DOI: 10.3748/wjg.v17.i20.2465]
159. You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol 2004; 34: 39-43 [PMID: 15670664 DOI: 10.1016/j.alcohol.2004.07.004]
160. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690 [PMID: 2648927]
161. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009; 15: 1613-1619 [PMID: 19340904 DOI: 10.3748/wjg.15.1613]
162. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-Adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990; 99: 211-215 [PMID: 2188871]
163. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-Activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 27997-28004 [PMID: 12791698 DOI: 10.1074/jbc.M302140200]
164. Kong L, Ren W, Li W, Zhao S, Mi H, Wang R, Zhang Y, Wu W, Nan Y, Yu J. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids Health Dis 2011; 10: 246 [PMID: 22208561 DOI: 10.1186/1476-51 1x-10-246]
165. Soylu AR, Altaner S, Aydodu N, Basaran UN, Tarcin O, Gedik N, Umit H, Tezel A, Ture M, Kutlu K, Kaymak K. Effects of vitamins E and C supplementation on hepatic glutathione peroxidase activity and tissue injury associated with ethanol ingestion in malnourished rats. Curr Ther Res Clin Exp 2006; 67: 118-137 [PMID: 24678089 DOI: 10.1016/j.curtheres.2006.04.007]
166. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology 2014; 60: 2099-2108 [PMID: 25164003 DOI: 10.1002/hep.27406]